Abstract
Curcumin, an active compound in turmeric and curry, has been proven to induce tumor apoptosis and inhibit tumor proliferation, invasion, angiogenesis, and metastasis via modulating numerous targets in various types of cancer cells. Aurora A is a mitosis-related serine-threonine kinase and plays important roles in diverse human cancers. However, the effect of curcumin on Aurora A has not been reported. In this study, Aurora A promoter activity and mRNA expression were inhibited in curcumin-treated human bladder cancer T24 cells, suggesting that Aurora A is regulated at the transcription level. We also found that curcumin preferentially inhibited the growth of T24 cells, which show a higher proliferation rate, invasion activity, and expression level of Aurora A compared with that of human immortalized uroepithelial E7cells. Furthermore, inhibition of phosphorylation of Aurora A and its downstream target histone H3 accompanied by the formation of monopolar spindle, induction of G2/M phase arrest, and reduction in cell division in response to curcumin were detected in T24 cells. These curcumin-induced phenomena were similar to those using Aurora A small interfering RNA and were attenuated by ectopic expression of Aurora A. Therefore, the antitumor mechanism of curcumin is Aurora A-related, which further supports the application of curcumin in treatments of human cancers.
Footnotes
↵
The online version of this article (available at http://molpharm.aspetjournals.org) contains supplemental material.
This work was supported by the National Science Council, Taiwan [Grants NSC 96-2313-B-309-001-MY2, NSC 98-2313-B-003-002-MY3, NSC-96-2628-B-006-003-MY3, NSC-99-2627-B-010-008]; the Ministry of Economic Affairs, Taiwan [Grant 99-EC-17-A-17-S1-152]; and the National Taiwan Normal University, Taiwan [Grant 99-D].
Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.
doi:10.1124/mol.111.072512.
-
ABBREVIATIONS:
- DMEM
- Dulbecco's modified Eagle medium
- FBS
- fetal bovine serum
- MTT
- 3-[4,5]-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
- RT
- reverse transcription
- PCR
- polymerase chain reaction
- siRNA
- small interfering RNA
- PI
- propidium iodide.
- Received March 27, 2011.
- Accepted July 14, 2011.
- Copyright © 2011 The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|